Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
- 1 February 2021
- journal article
- editorial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (2), 237-+
- https://doi.org/10.7326/M20-7945
Abstract
Cannabis includes 140 active cannabinoid compounds, the most important of which are tetrahydrocannabinol and cannabidiol (CBD). Tetrahydrocannabinol is primarily responsible for the intoxicating effects of cannabis; CBD has potential therapeutic effects, including reduction in chronic pain. Recent legislative changes have resulted in the legal availability of cannabinoids in all 50 states, as well as a marked increase in patients' interest in their use. Despite an abundance of data, albeit of varied quality, clinicians may feel poorly prepared to counsel patients seeking advice on the suitability of CBD products for various indications, particularly chronic neuropathic pain. In 2018, on the basis of a systematic review of the literature, a Canadian Evidence Review Group published a guideline with recommendations for clinicians on prescribing cannabinoids in primary care practice. The overall quality of evidence was low to very low. In a meta-analysis of 15 randomized trials of medical cannabis for treating chronic pain, 39% of patients achieved at least a 30% reduction in pain. The corresponding value for placebo-treated patients was 30%; the number needed to treat was 11. More evidence exists for neuropathic pain than for other types of noncancer pain. Here, a general internist with a focus on addiction medicine and an addiction psychiatrist discuss how they would apply the literature to make recommendations for a patient with painful diabetic neuropathy, including counseling on both potential benefits and harms.This publication has 33 references indexed in Scilit:
- Cannabis use and neurocognitive functioning in a non-clinical sample of usersAddictive Behaviors, 2014
- Persistent cannabis users show neuropsychological decline from childhood to midlifeProceedings of the National Academy of Sciences of the United States of America, 2012
- A Double-Blind Randomized Controlled Trial ofN-Acetylcysteine in Cannabis-Dependent AdolescentsAmerican Journal of Psychiatry, 2012
- Effect of long-term cannabis use on axonal fibre connectivityBrain, 2012
- Age of onset of marijuana use impacts inhibitory processingNeuroscience Letters, 2012
- A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent AdultsNeuropsychopharmacology, 2012
- Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysisBMJ, 2012
- Association Between Marijuana Exposure and Pulmonary Function Over 20 YearsJAMA, 2012
- An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive FunctionsJournal of Addiction Medicine, 2011
- Cannabis and anxiety: a critical review of the evidenceHuman Psychopharmacology: Clinical and Experimental, 2009